Standard vs adapted sunitinib regimen in elderly patients with metastatic renal cell cancer: results from a large retrospective analysis.

Abstract:

BACKGROUND:There are no data on the patterns of care and outcome of elderly patients with mRCC treated with sunitinib. In a retrospective study, we assessed the routine use of first-line sunitinib in mRCC patients aged ≥ 70 years. PATIENTS AND METHODS:We reviewed the clinical files of 185 patients aged ≥ 70 years with mRCC treated with first-line sunitinib in 17 Italian oncology units from February 2006 to September 2011. One hundred twenty-three patients (66.5%) received a standard 50 mg/d for a 4 weeks on/2 weeks off regimen (SR), and 62 patients (33.5%) received an AR consisting of 37.5 mg/d for a 4 weeks on/2 weeks off in 67.7% of cases. RESULTS:Median age was 74 years. Patients treated with an AR were older than those treated with the SR (P < .0001). In the overall population, the median progression-free survival (PFS) was 11 months, and the median overall survival (OS) was 25.5 months. Grade 3-4 toxicities occurred in 87 of 123 SR (70.7%) and 32 of 62 AR (51.6%), respectively; dose reductions were required in 82 SR (66.7%) and 26 AR (41.9%), respectively; discontinuations because of therapy-related adverse events occurred in 25 SR (20.3%) and 15 AR (24.2%), respectively. In multivariate analysis, only performance status and the Heng score were predictors of either PFS or OS. CONCLUSION:Sunitinib is active and feasible in elderly patients with mRCC. A sunitinib AR could be considered as an option in selected older mRCC patients. The optimal treatment of frail patients with mRCC remains to be established.

journal_name

Clin Genitourin Cancer

authors

De Giorgi U,Scarpi E,Sacco C,Aieta M,Lo Re G,Sava T,Masini C,De Vincenzo F,Baldazzi V,Camerini A,Fornarini G,Burattini L,Rosti G,Ferrari V,Moscetti L,Chiuri VE,Luzi Fedeli S,Amadori D,Basso U

doi

10.1016/j.clgc.2013.11.005

subject

Has Abstract

pub_date

2014-06-01 00:00:00

pages

182-9

issue

3

eissn

1558-7673

issn

1938-0682

pii

S1558-7673(13)00276-0

journal_volume

12

pub_type

杂志文章
  • An Analysis of Staging and Treatment Trends for Upper Tract Urothelial Carcinoma in the National Cancer Database.

    abstract:BACKGROUND:The purpose of this study was to analyze contemporary trends for diagnosis and treatment of upper tract urothelial carcinoma (UTUC). PATIENTS AND METHODS:We identified all cases of UTUC in the National Cancer Database (NCDB) between 2004 and 2013. Data comprising tumor, patient, and facility factors were ex...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2018.01.015

    authors: Browne BM,Stensland KD,Moynihan MJ,Canes D

    更新日期:2018-08-01 00:00:00

  • Effect of Bleomycin Administration on the Development of Pulmonary Toxicity in Patients With Metastatic Germ Cell Tumors Receiving First-Line Chemotherapy: A Meta-Analysis of Randomized Studies.

    abstract:BACKGROUND:Limited information is available about the effect of bleomycin administration on the development of pulmonary toxicity in metastatic germ cell tumors (GCT). PATIENTS AND METHODS:A literature search was conducted to identify randomized trials of first-line chemotherapy for GCT. We conducted univariate and mu...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,meta分析

    doi:10.1016/j.clgc.2016.08.021

    authors: Necchi A,Miceli R,Oualla K,Sonpavde G,Giannatempo P,Raggi D,Nicolai N,Boffi R,Busia A,Mariani L,Salvioni R

    更新日期:2017-04-01 00:00:00

  • Fourteen-Core Systematic Biopsy That Includes Two Anterior Cores in Men With PI-RADS Lesion ≥ 3 is Comparable With Magnetic Resonance Imaging-ultrasound Fusion Biopsy in Detecting Clinically Significant Prostate Cancer: A Single-institution Experience.

    abstract:INTRODUCTION:Magnetic resonance imaging (MRI)-ultrasound fusion targeted prostate biopsy (FB) has been advocated by many experts as a replacement for the standard template biopsy. Herein, we compared pathology results and cancer detection rates of FB with our standard 14-core systematic prostate biopsy (SB) that includ...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2020.09.006

    authors: Sterling J,Smith K,Farber N,Nagaya N,Jang TL,Singer EA,Sadimin E,Kim IY

    更新日期:2020-10-13 00:00:00

  • Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma.

    abstract:BACKGROUND:There is a lack of molecularly-informed biomarkers for patients with metastatic renal cell carcinoma (RCC). Plasma cell-free DNA (cfDNA) sequencing is a minimally-invasive alternative to tissue for profiling the genome in other cancers but relevance in metastatic RCC remains unclear. MATERIALS AND METHODS:W...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.12.018

    authors: Bacon JVW,Annala M,Soleimani M,Lavoie JM,So A,Gleave ME,Fazli L,Wang G,Chi KN,Kollmannsberger CK,Wyatt AW,Nappi L

    更新日期:2020-08-01 00:00:00

  • Programmed Death-Ligand 1 Expression in Muscle-Invasive Bladder Cancer Cystectomy Specimens and Lymph Node Metastasis: A Reliable Treatment Selection Biomarker?

    abstract:BACKGROUND:The programmed death-1 (PD-1) pathway negatively regulates T-cell activation and has an important role in regulating antitumor host immunity. Monoclonal antibodies directed against PD-1 or the PD-1 ligand (PD-L1) have shown activity in several tumor types with preliminary data suggesting a relationship betwe...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2015.12.002

    authors: Mukherji D,Jabbour MN,Saroufim M,Temraz S,Nasr R,Charafeddine M,Assi R,Shamseddine A,Tawil AN

    更新日期:2016-04-01 00:00:00

  • Detection and Clinical Significance of Circulating Tumor Cells in Patients Undergoing Radical Cystectomy for Urothelial Bladder Cancer.

    abstract:INTRODUCTION:Estimation of prognosis is patients undergoing radical cystectomy is often unreliable, as occult disease remains undetected by conventional diagnostic tools. The purpose of this study was to evaluate the feasibility and the clinical significance of a polymerase chain reaction assay to detect cytokeratin 7 ...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2016.11.005

    authors: Pagliarulo V,Ancona P,Petitti T,Salerno A,Spadavecchia R,Di Stasi S,Cormio L,Maurizio B,Carrieri G,Ditonno P

    更新日期:2017-08-01 00:00:00

  • Risk for Venous Thromboembolic Events in Patients With Advanced Urinary Tract Cancer Treated With First-Line Chemotherapy.

    abstract:BACKGROUND:Venous thromboembolic events (VTEs) frequently occur in cancer patients. Risk assessment models (RAMs) for cancer-associated thrombosis have been proposed. However, advanced urinary tract cancer (aUTC) was not adequately represented in these models. We studied the incidence of VTEs, the risk factors, and the...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.12.021

    authors: Bamias A,Tzannis K,Dimitriadis I,Tsironis G,Papatheorodidi AM,Tsiara A,Fragkoulis C,Xirokosta A,Barbarousi D,Papadopoulos G,Zakopoulou R,Varkarakis I,Mitsogiannis I,Adamakis I,Alamanis C,Stravodimos K,Papatsoris AG,Dell

    更新日期:2020-08-01 00:00:00

  • The Prognostic Value of Tumor Regression Grades Combined With TNM Classification in Patients With Muscle-Invasive Bladder Cancer Who Underwent Neoadjuvant Chemotherapy Followed by Radical Cystectomy.

    abstract:INTRODUCTION:Tumor regression grades (TRGs) quantify the pathologic response to neoadjuvant chemotherapy (NAC). The aim of the study was to investigate the prognostic value of TRGs in combination with the TNM classification in an independent cohort of patients with muscle-invasive bladder cancer (MIBC) treated with NAC...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.09.003

    authors: Gronostaj K,Czech AK,Fronczek J,Drobniak A,Okon K,Chlosta PL,Szczeklik W

    更新日期:2019-12-01 00:00:00

  • Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical Trials.

    abstract:BACKGROUND:We characterized clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib who were long-term responders (LTRs), defined as patients having progression-free survival (PFS) > 18 months. PATIENTS AND METHODS:A retrospective analysis of data from 5714 patients with mRCC t...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2017.06.005

    authors: Tannir NM,Figlin RA,Gore ME,Michaelson MD,Motzer RJ,Porta C,Rini BI,Hoang C,Lin X,Escudier B

    更新日期:2017-06-20 00:00:00

  • Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community.

    abstract:BACKGROUND:Renal dysfunction, poor performance status, and comorbidities may preclude frontline cisplatin-based chemotherapy in patients with advanced urothelial carcinoma (UC). The frequency of cisplatin-based chemotherapy administration in patients with advanced UC in community-based cancer centers is unknown. PATIE...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2011.11.005

    authors: Sonpavde G,Watson D,Tourtellott M,Cowey CL,Hellerstedt B,Hutson TE,Zhan F,Vogelzang NJ

    更新日期:2012-03-01 00:00:00

  • Upper urinary tract transitional cell carcinoma: is there a best?

    abstract:BACKGROUND:This study aimed to determine the prognostic and risk factors for bladder and systemic recurrence after nephroureterectomy (NU) in patients with upper urinary tract (UUT) transitional cell carcinoma (TCC). PATIENTS AND METHODS:Data from 101 patients with nonmetastatic UUT TCC who underwent NU between 1987 a...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2012.08.009

    authors: Gunay LM,Akdogan B,Koni A,Inci K,Bilen CY,Ozen H

    更新日期:2013-03-01 00:00:00

  • Identification of Differential Patterns of Oxidative Biomarkers in Prostate Cancer Progression.

    abstract:INTRODUCTION:Oxidative stress has been found to be associated with the progression of prostate cancer (PCa); however, human studies which identify differential roles of each oxidation pathway in PCa progression are lacking. We aimed to identify which oxidative stress markers, specifically lipid and global oxidation and...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.09.014

    authors: Wu T,Kasper S,Wong RM,Bracken B

    更新日期:2020-04-01 00:00:00

  • Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy.

    abstract::Effective options are lacking for progressive castration-refractory prostate cancer (CRPC) after conventional chemotherapy. Sunitinib is an orally administered multitargeted tyrosine kinase inhibitor that is approved multinationally for renal cell carcinoma and gastrointestinal stromal tumors. A phase II trial was con...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,多中心研究

    doi:10.3816/CGC.2008.n.023

    authors: Sonpavde G,Hutson TE,Berry WR,Boehm KA,Asmar L

    更新日期:2008-09-01 00:00:00

  • Tyrosine kinase inhibitors compared with cytokine therapy for metastatic renal cell carcinoma: overview of recent clinical trials differentiating clinical response and adverse effects.

    abstract::Metastatic renal cell carcinoma has long been recognized as an aggressive, therapy-refractory epithelial cancer. Two decades of clinical experience with the biologic response modifiers, such as interferon and interleukin-2, have produced little in the way of clinically meaningful benefit for patients, with the notable...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,评审

    doi:10.3816/cgc.2006.s.003

    authors: Dreicer R

    更新日期:2006-12-01 00:00:00

  • Potential Effect of Antiplatelet and Anticoagulant Therapy on the Timing of the Diagnosis of Bladder Cancer.

    abstract:BACKGROUND:The most common presenting symptom of bladder cancer (BCa) is hematuria. The present study was designed to define whether patients taking antiplatelet and/or anticoagulant drugs might experience hematuria at an earlier stage or grade of BCa. PATIENTS AND METHODS:The data from 1532 consecutive patients who p...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2015.08.003

    authors: Moschini M,Karnes RJ,Suardi N,Bianchi M,Pellucchi F,Rocchini L,Damiano R,Serretta V,Salonia A,Montorsi F,Briganti A,Colombo R

    更新日期:2016-06-01 00:00:00

  • Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma.

    abstract::The use of sunitinib in dialysis patients is poorly described but is of clinical importance. We report 2 cases of patients receiving sunitinib for metastatic renal cell carcinoma while undergoing dialysis. The first patient is undergoing hemodialysis and, though responding to sunitinib, is having significant fatigue a...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.3816/CGC.2009.n.035

    authors: Vickers MM,Heng DY,Hemmelgarn B,Eigl BJ

    更新日期:2009-10-01 00:00:00

  • Effect of perioperative blood transfusion on mortality for major urologic malignancies.

    abstract:INTRODUCTION:Patients who undergo surgical treatment for malignancy often receive perioperative blood transfusion (PBT). We examined the association between PBT and mortality in patients who received surgical treatment of prostate, bladder, and kidney cancer. MATERIALS AND METHODS:Using the Surveillance, Epidemiology,...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2014.12.006

    authors: Soubra A,Zabell JR,Adejoro O,Konety BR

    更新日期:2015-06-01 00:00:00

  • Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors.

    abstract:BACKGROUND:Venous thromboembolism (VTE) is common in cancer patients, but there is limited data on patients with urothelial tract tumors (UTT). We previously identified several associative factors for increased VTE rates in patients with metastatic UTT. In this study, we assessed the frequency, associative factors, and...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2017.08.001

    authors: Ramos JD,Wingate JT,Gulati R,Plimack ER,Harshman LC,Powles T,Crabb SJ,Niegisch G,Bellmunt J,Ladoire S,De Giorgi U,Hussain S,Alva AS,Baniel J,Agarwal N,Rosenberg JE,Vaishampayan UN,Galsky MD,Yu EY,RISC Investigators.

    更新日期:2017-08-24 00:00:00

  • Effect of Diphosphonates on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer.

    abstract::Patients receiving androgen deprivation therapy are associated with increasing loss of bone mineral density (BMD) and higher risk of skeletal-related events. We reviewed and analyzed the influence of diphosphonates on BMD change. A systemic literature research was conducted in PubMed and related bibliographies. The fo...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,meta分析,评审

    doi:10.1016/j.clgc.2018.07.016

    authors: Wu C,Chen W,Huang X,Lin R,Wu J,Zhang X

    更新日期:2018-12-01 00:00:00

  • Comparative Effectiveness of Intravesical BCG-Tice and BCG-Moreau in Patients With Non-muscle-invasive Bladder Cancer.

    abstract:BACKGROUND:The purpose of this study was to compare the efficacy of 2 bacillus Calmette-Guérin (BCG) strains, BCG-Tice and BCG-Moreau, in the treatment of non-muscle-invasive bladder cancer (NMIBC). MATERIALS AND METHODS:We retrospectively reviewed clinical data from patients treated with BCG for NMIBC at 3 academic c...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.clgc.2019.10.021

    authors: D'Andrea D,Soria F,Abufaraj M,Pones M,Gontero P,Machado AT,Waksman R,Enikeev DV,Glybochko PV,Adonias SP,Nahas WC,Shariat SF,Chade DC

    更新日期:2020-02-01 00:00:00

  • Global Quality of Life After Curative Treatment for Prostate Cancer: What Matters? A Study Among Members of the Norwegian Prostate Cancer Patient Association.

    abstract:INTRODUCTION:The purpose of this study was to identify factors that are associated with quality of life (QoL) in relapse-free patients after radical prostatectomy or high-dose radiotherapy with or without hormone treatment. PATIENTS AND METHODS:A cross-sectional postal survey among members of the Norwegian Prostate Ca...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2015.07.004

    authors: Fosså SD,Dahl AA

    更新日期:2015-12-01 00:00:00

  • Comparison of Laparoscopic and Robot-assisted Radical Cystectomy for Bladder Cancer: Perioperative and Oncologic Outcomes.

    abstract:BACKGROUND:The purpose of this study was to compare perioperative and oncologic outcomes between laparoscopic radical cystectomy (LRC) and robot-assisted radical cystectomy (RARC) for bladder cancer (BCa). MATERIALS AND METHODS:Patients who underwent LRC or RARC with curative intent for BCa between January 2011 and De...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.06.007

    authors: Su S,Gu L,Ma X,Li H,Wang B,Shi T,Zhang X

    更新日期:2019-10-01 00:00:00

  • Neoadjuvant Radiotherapy Improves Survival in Patients With T2b/T3 Bladder Cancer: A Population-Based Analysis.

    abstract:BACKGROUND:Neoadjuvant radiotherapy (NART) for muscle-invasive bladder cancer (MIBC) is currently underused. However, the outcomes for MIBC have remained suboptimal. We investigated the relationship of NART to cause-specific mortality (CSM) and overall mortality (OM) among patients with a diagnosis of MIBC. MATERIALS ...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2015.02.014

    authors: Diaz DA,Pollack A,Reis IM,Mahmoud O,Gonzalgo ML,Ishkanian A,Fernandez G,Manoharan M,Abramowitz MC

    更新日期:2015-08-01 00:00:00

  • Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis.

    abstract:BACKGROUND:Results from large randomized controlled trials combining docetaxel, abiraterone, celecoxib, or bisphosphonates with androgen deprivation therapy (ADT) in hormone-sensitive prostate cancer have emerged. However, in our knowledge, few data are available in patients older than 70 years. Therefore, we undertook...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,meta分析

    doi:10.1016/j.clgc.2019.05.001

    authors: Landre T,Guetz GD,Chouahnia K,Fossey-Diaz V,Taleb C,Culine S

    更新日期:2019-08-01 00:00:00

  • Influence of body mass index and smoking on the long-term survival of patients with renal cell cancer.

    abstract:BACKGROUND:Smoking and obesity are known risk factors for renal cell carcinoma (RCC). We determined the influence of smoking, body mass index (BMI), and symptoms on the survival of patients with RCC. PATIENTS AND METHODS:In this retrospective study, the relative overall survival (OS) up to 25 years was calculated amon...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2013.04.017

    authors: Sunela KL,Kataja MJ,Kellokumpu-Lehtinen PL

    更新日期:2013-12-01 00:00:00

  • Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma.

    abstract:BACKGROUND:Combination platinum chemotherapy is standard first-line therapy for metastatic urothelial carcinoma (mUC). Defining the platinum response biomarkers for patients with mUC could establish personalize medicine and provide insights into mUC biology. Although DNA repair mechanisms have been hypothesized to medi...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2015.12.029

    authors: Mullane SA,Werner L,Guancial EA,Lis RT,Stack EC,Loda M,Kantoff PW,Choueiri TK,Rosenberg J,Bellmunt J

    更新日期:2016-08-01 00:00:00

  • Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma.

    abstract:PURPOSE:Similar to other molecularly targeted agents, temsirolimus, an inhibitor of mammalian target of rapamycin, has shown promising activity in advanced renal cell carcinoma. However, only a subset of patients appears to derive significant tumor responses. In an effort to identify potential predictors of response to...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.3816/CGC.2007.n.020

    authors: Cho D,Signoretti S,Dabora S,Regan M,Seeley A,Mariotti M,Youmans A,Polivy A,Mandato L,McDermott D,Stanbridge E,Atkins M

    更新日期:2007-09-01 00:00:00

  • Phase II study of azacitidine to restore responsiveness of prostate cancer to hormonal therapy.

    abstract::Epigenetic alterations, including methylation of key tumor suppressor genes, may play a role in the progression of prostate cancer to a castration-refractory state. Azacitidine, an agent approved for the treatment of myelodysplastic syndromes, appears to exert its antineoplastic effects partly by hypomethylating DNA t...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.3816/CGC.2007.n.036

    authors: Sonpavde G,Aparicio A,Guttierez I,Boehm KA,Hutson TE,Berry WR,Asmar L,von Hoff DD

    更新日期:2007-12-01 00:00:00

  • Prognostic Value of Lactate Dehydrogenase in Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.

    abstract::The purpose of this study was to assess the prognostic value of lactate dehydrogenase (LDH) in patients with metastatic prostate cancer (PC). A systematic review and meta-analysis was performed in March 2019 according to the Preferred Reporting Items for Systematic Review and Meta-analysis statement. Studies were deem...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,meta分析

    doi:10.1016/j.clgc.2019.07.009

    authors: Mori K,Kimura S,Parizi MK,Enikeev DV,Glybochko PV,Seebacher V,Fajkovic H,Mostafaei H,Lysenko I,Janisch F,Egawa S,Shariat SF

    更新日期:2019-12-01 00:00:00

  • Comparison of Patient-Reported Quality-of-Life and Complications in Men With Prostate Cancer, Between Two Modes of Administration.

    abstract:INTRODUCTION:Our purpose was to: (1) assess the level of consistency between the quality-of-life (QOL) scores of men with prostate cancer for urinary/bowel/sexual bother, collected via telephone versus self-administered survey; (2) determine factors associated with variation in level of agreement; and (3) assess the ef...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2015.12.016

    authors: Sampurno F,Ruseckaite R,Millar JL,Evans SM

    更新日期:2016-08-01 00:00:00